If you have knee osteoarthritis, you’ve probably been told the same things: lose weight, take painkillers, try physiotherapy, consider a cortisone injection. And if it gets bad enough — surgery.
What most people are never told is that none of these treatments actually change what’s happening inside the joint. They manage the pain. They don’t address the biology driving it. That’s what makes stem cell therapy — specifically UC-MSC therapy — a genuinely different conversation. Not because it’s a miracle. But because it’s the first approach that attempts to work with the biology of the joint itself, rather than around it.
This article explains how it works, why the science behind it matters, and what it means for people living with knee pain.
Why Knee Osteoarthritis Is Such a Difficult Problem
Knee osteoarthritis is one of the most common degenerative joint conditions in the world — and medicine has struggled to do much about it.
No treatment currently exists to stop or reverse osteoarthritis progression — existing options manage symptoms, not the disease itself.
The breakdown starts with cartilage, which has no blood supply and cannot self-repair. Damage simply accumulates. It also triggers chronic joint inflammation — a cycle where inflammation accelerates cartilage loss, and cartilage loss drives more inflammation.
Conventional treatments interrupt this cycle temporarily. Regenerative medicine is exploring whether it can go deeper.
What Are UC-MSCs and Why Do They Matter for Knee OA?
MSCs have attracted growing research interest in osteoarthritis for two reasons: their ability to differentiate into cartilage-forming cells, and their capacity to modulate immune activity inside the joint.
UC-MSCs, sourced from donated umbilical cord tissue, offer higher cell yield, stronger proliferation, and lower rejection risk than bone marrow or fat-derived alternatives — with no harvesting procedure required from the patient.
A 2025 systematic review in Stem Cells International identified UC-MSCs as a promising regenerative approach for knee OA, particularly given how limited conventional cartilage repair options remain.
How UC-MSCs Actually Work Inside the Knee
This is where the science becomes important to understand — not because the mechanisms are complicated, but because they explain why this therapy is categorically different from a painkiller or a steroid injection. UC-MSCs work through several pathways simultaneously.
Controlling inflammation at the source
The inflammation driving osteoarthritis is sustained by specific proteins — including TNF-α and IL-1β — that actively accelerate cartilage breakdown. UC-MSCs counter this by secreting anti-inflammatory cytokines that suppress these signals.
The result is reduced pain and swelling — not because it’s been masked, but because the biological process generating it has been slowed.
Creating the right environment for cartilage to recover
UC-MSCs also secrete growth factors that support cartilage cell survival and stimulate production of the structural material keeping the joint cushioned — creating conditions for the joint’s own repair mechanisms to function.
Evidence suggests UC-MSCs are most effective in early to moderate OA, before the joint environment is too compromised to respond. This is why earlier intervention, even before pain becomes severe, is increasingly considered clinically relevant.
Slowing degeneration before it becomes irreversible
Studies have shown that UC-MSC treatment is most effective before degeneration has fully advanced — reducing cartilage damage and improving joint structure in early-stage OA more significantly than in later stages.
These findings don’t mean stem cell therapy can cure osteoarthritis or guarantee progression stops. The research is still maturing and outcomes vary. What they do suggest is that this therapy operates at a biological level conventional treatments don’t reach.
What the Clinical Evidence Looks Like
Clinical studies evaluating UC-MSC injections for knee OA have reported meaningful reductions in pain and improvements in function — with results comparing favourably to conventional treatments like hyaluronic acid.
Safety has been reassuring across the literature. Side effects are mild and temporary, most commonly brief discomfort or swelling at the injection site. No serious adverse events have been reported to date.
Researchers have also noted stronger outcomes with earlier intervention — before significant joint deterioration — shifting thinking away from waiting until surgery is the only option.
Who This Type of Treatment Is Relevant For
UC-MSC therapy is not right for every patient or every stage of knee OA. At EDNA Wellness, all cases are reviewed by orthopedic surgeons before any recommendation is made. Stem cell therapy is one option among several — suggested only when appropriate for the individual.
Those most likely to benefit are patients in the early to moderate stages — where cartilage damage is present but the joint has not yet severely deteriorated. Patients who haven’t responded to physiotherapy or conventional injections, or who want to explore alternatives before surgery, are also good candidates for evaluation.
The goal is not to replace other treatments. It’s to offer stem cell therapy where the evidence supports it, with the clinical judgment to know when it does and when it doesn’t.
A Note on Realistic Expectations
UC-MSC therapy cannot reverse advanced joint destruction or guarantee cartilage regeneration. Outcomes vary by age, severity, and lifestyle.
What the research does support is that it can reduce inflammation, slow cartilage degeneration, and improve pain and function — particularly in earlier stages. For many patients, that means meaningful relief without surgery.
If you’re wondering whether this is right for you, the best starting point is an evaluation by a surgeon who can assess your joint and give you an honest answer.
About EDNA Wellness
EDNA Wellness is a surgeon-led regenerative medicine center in Bangkok, specializing in orthopedic and neurological conditions using Umbilical Cord–Derived Mesenchymal Stem Cells (UC-MSCs).
All cases are reviewed by orthopedic surgeons and neurosurgeons, with a focus on clinical indication, patient safety, and realistic treatment expectations. Stem cell therapy is recommended selectively, and alternative treatments are considered when more appropriate.
For more information or to book a consultation:
LINE: @ednawellness
WhatsApp: +66 (0) 64 505 5599
www.ednawellness.com
References
- Lohrasbi V, et al. Regenerative Therapy in Osteoarthritis Using Umbilical Cord-Origin Mesenchymal Stem Cells: A Critical Appraisal of Clinical Safety and Efficacy Through Systematic Review and Meta-Analysis. Stem Cells International. 2025;4261166. https://doi.org/10.1155/sci/4261166
- Espinoza F, et al. A Phase I/II, Randomized, Double-blind, Controlled Study to Assess Safety and Efficacy of Umbilical Cord-derived Mesenchymal Stromal Cells (UC-MSCs) in Patients With Knee Osteoarthritis. ClinicalTrials.gov Identifier: NCT02580695. https://clinicaltrials.gov/study/NCT02580695
- Li M, et al. Repeated intra-articular injections of umbilical cord-derived mesenchymal stem cells for knee osteoarthritis: a phase I, single-arm study. Stem Cell Research & Therapy. 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262357/
- Boyce M, et al. Intra-Articular Injection of Human Umbilical Cord-Derived Mesenchymal Stromal Cells Reduces Radiographic Osteoarthritis in an Ovine Model. Cartilage. 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11556672/
- Wang X, et al. Human Umbilical Cord Mesenchymal Stem Cells Inhibit the Progression of Osteoarthritis by Suppressing NLRP3-Mediated Synovial Inflammation in the Early Stages of the Disease. Frontiers in Immunology. 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12413943/
- Xiang XN, et al. Mesenchymal stromal cell-based therapy for cartilage regeneration in knee osteoarthritis. Stem Cell Research & Therapy. 2022;13(1):14. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751117/
- Rodríguez-Merchán EC. Intraarticular Injections of Mesenchymal Stem Cells in Knee Osteoarthritis: A Review of Their Current Molecular Mechanisms of Action and Their Efficacy. International Journal of Molecular Sciences. 2022;23(23):14953. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9740663/
- Perán M, et al. A Systematic Review of the Safety and Efficacy of Wharton’s Jelly-Derived MSC Treatments in Knee Osteoarthritis and Cartilage Injury. Journal of Clinical Medicine. 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11942840/